Resumo

ALARCON-SOTELO, Alejandra et al. Up-to-date in the long-term pharmacological treatment of obesity. A therapeutic option?. Med. interna Méx. [online]. 2018, vol.34, n.6, pp.946-958. ISSN 0186-4866.  https://doi.org/10.24245/mim.v34i6.2022.

Obesity is a chronic disease, with systemic affection and of multifactorial character that constitutes a serious problem of public health, being considered by the World Health Organization a global epidemic. Obesity is the result of a positive energy balance by a long time, where the energy derived from food exceeds the energy expended in everyday life. In order to put an end to this public health problem, treatment options have been sought, although the modifications to the lifestyle included diet and exercise are still the cornerstone of the treatment for obesity, these modifications have not allowed to maintain long-term results; for this reason anti-obesity drugs become a viable option. There are five drugs approved by the FDA nowadays for the long-term treatment of obesity: orlistat, phentermine/topiramate prolonged release, lorcarserin, naltrexone/bupropion prolonged release, and liraglutide, which have shown efficacy and the necessary safety to be taken into account as a therapeutic option. In this article we will review the effectiveness and safety of each of the approved anti-obesity drugs that are available.

Palavras-chave : Obesity; Overweight; Antiobesity drugs; Weight loss.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )